A meta-analysis of 736 women found that breastfeeding changes specific molecules in the blood that protect against ovarian cancer. According to Gram Research analysis, women with the highest levels of breastfeeding-related molecules had 38% lower ovarian cancer risk compared to those with the lowest levels. Two types of molecules, phosphatidylcholines and phosphatidylethanolamines, showed the strongest protective association with breastfeeding duration.
Researchers discovered that breastfeeding changes the chemicals in a woman’s body in ways that may protect against ovarian cancer. Scientists studied nearly 750 women with ovarian cancer and compared them to women without the disease, looking at blood samples to identify specific molecules linked to breastfeeding. According to Gram Research analysis, women who breastfed longer had different patterns of these protective molecules, particularly types called phosphatidylcholines and phosphatidylethanolamines. The study combined data from multiple large health studies and found that women with the highest levels of breastfeeding-related molecules had about 38% lower risk of developing ovarian cancer compared to those with the lowest levels.
Key Statistics
A meta-analysis combining data from 736 women found that the highest levels of breastfeeding-related molecules were associated with an odds ratio of 0.62 for ovarian cancer, representing 38% lower risk compared to the lowest levels.
Among 14 breastfeeding-associated metabolites identified in one study of 436 women, 11 showed similar patterns in a second population of 663 postpartum women, demonstrating consistent biological changes across different groups.
Phosphatidylcholine and phosphatidylethanolamine metabolite pathways showed the strongest enrichment with breastfeeding, with normalized enrichment scores of 1.94 and 1.82 respectively in a 2026 meta-analysis.
Ten individual metabolites were positively associated with breastfeeding duration and inversely associated with ovarian cancer risk, suggesting coordinated changes across multiple metabolic pathways.
The Quick Take
- What they studied: Whether specific chemicals in the blood that change during breastfeeding could explain why breastfeeding protects women from ovarian cancer.
- Who participated: Two groups of women: 436 nurses from health studies who either developed ovarian cancer or didn’t, and 300 women from a cancer screening study. Researchers also looked at blood samples from 606 women in their mid-life and 663 women one year after giving birth.
- Key finding: Women with the highest levels of breastfeeding-related molecules had 38% lower ovarian cancer risk compared to women with the lowest levels. Ten specific molecules were linked to both longer breastfeeding and lower cancer risk.
- What it means for you: This research helps explain one biological reason why breastfeeding may protect against ovarian cancer. While this doesn’t change current health recommendations, it provides scientists with new targets for understanding and potentially preventing this cancer. Talk to your doctor about your personal cancer risk factors.
The Research Details
Researchers used a case-control study design, meaning they compared women who developed ovarian cancer to similar women who didn’t. They looked at blood samples collected years before cancer diagnosis to identify which molecules were different between the two groups. The study combined data from two major health studies of nurses and a cancer screening trial, then performed a meta-analysis to combine the results and make them more reliable.
The scientists measured 606 different molecules in blood samples from women in their mid-life and 663 molecules from women one year after giving birth. They identified which molecules were associated with breastfeeding, then checked whether those same molecules were also linked to lower ovarian cancer risk. This approach helped them discover a pattern: certain molecules increase with breastfeeding and decrease cancer risk.
This research design is powerful because it uses blood samples collected before women developed cancer, so the molecules measured couldn’t have been caused by the cancer itself. By combining data from multiple studies, researchers increased confidence in their findings. Identifying specific molecules helps scientists understand the actual biological mechanisms behind the breastfeeding-cancer protection link, which could eventually lead to new prevention strategies.
The study’s strengths include using blood samples collected before cancer diagnosis, combining data from multiple large health studies, and measuring molecules in two different populations to confirm findings. The sample size of 736 women with cancer is reasonably large for this type of research. However, the study was observational, meaning researchers couldn’t prove that these molecules directly cause the cancer protection. The confidence interval for the main finding (0.39-0.99) just barely includes 1.0, suggesting moderate certainty in the result.
What the Results Show
Women in the highest group for breastfeeding-related molecules had an odds ratio of 0.62, meaning they had 38% lower odds of developing ovarian cancer compared to women in the lowest group. This finding combined data from two separate studies and was statistically significant, though the confidence interval suggests moderate certainty.
Two specific types of molecules, phosphatidylcholines and phosphatidylethanolamines, showed the strongest connection to breastfeeding. These molecules increased in women who breastfed longer and were also associated with lower cancer risk. Ten individual molecules showed this pattern: they increased with breastfeeding and decreased cancer risk, suggesting these molecules may be part of the protective mechanism.
When researchers looked at 14 molecules associated with breastfeeding in one study, they found that 11 of these same molecules showed similar patterns in a second population of postpartum women. This consistency across different groups of women strengthens confidence in the findings.
The research identified specific metabolite pathways, or chemical processes in the body, that change with breastfeeding. Phosphatidylcholine and phosphatidylethanolamine pathways showed the strongest enrichment, meaning many molecules in these pathways were affected by breastfeeding. This suggests that breastfeeding triggers coordinated changes across multiple related chemical systems rather than affecting just one or two molecules.
Previous research has clearly shown that breastfeeding reduces ovarian cancer risk by about 30% for every 12 months of breastfeeding. However, scientists didn’t understand the biological reason why. This study provides a potential explanation by identifying specific molecules and chemical pathways that may be responsible. The findings align with earlier research showing that breastfeeding affects hormone levels and immune function, but this is the first study to map specific metabolites to the cancer protection effect.
The study was observational, so researchers cannot prove that these molecules directly cause cancer protection. The confidence interval for the main finding just barely excludes 1.0, indicating moderate statistical certainty. The study included mostly white women from health professional populations, so results may not apply equally to all racial and ethnic groups. Researchers measured molecules at one point in time, so they couldn’t track how these molecules change over years. The biological mechanisms explaining why these specific molecules protect against cancer remain unclear and require further research.
The Bottom Line
Current health organizations already recommend breastfeeding for multiple health benefits including ovarian cancer risk reduction. This research provides additional biological explanation for that recommendation but doesn’t change clinical guidance. Women concerned about ovarian cancer risk should discuss their personal risk factors with their doctor. This research is primarily important for scientists developing future cancer prevention strategies.
Women of reproductive age, particularly those with family history of ovarian cancer, should know that breastfeeding offers protective benefits. Healthcare providers should understand the biological mechanisms behind breastfeeding’s cancer protection. Researchers studying cancer prevention and metabolic health should use these findings to develop new prevention approaches. Women who cannot breastfeed should not feel concerned, as many other factors influence cancer risk.
The protective effect of breastfeeding on ovarian cancer risk develops over years and decades. This study measured molecules at one point in time, so it doesn’t show how quickly these protective changes occur. The cancer-protective benefit typically appears in studies following women for 10 to 20 years after breastfeeding.
Frequently Asked Questions
Does breastfeeding actually prevent ovarian cancer?
Breastfeeding significantly reduces ovarian cancer risk by about 30% for every 12 months of breastfeeding. This 2026 study found that women with the highest breastfeeding-related molecules had 38% lower cancer risk, providing biological explanation for this protective effect.
What are phosphatidylcholines and phosphatidylethanolamines?
These are types of fat molecules found in cell membranes throughout your body. Breastfeeding increases these molecules in the bloodstream, and they appear to protect against ovarian cancer. They’re part of your body’s natural chemical signaling systems.
Can I reduce my ovarian cancer risk without breastfeeding?
Yes, multiple factors reduce ovarian cancer risk including using hormonal birth control, having children, maintaining healthy weight, and regular exercise. Breastfeeding is one protective factor among many. Discuss your personal risk factors with your doctor.
How long do I need to breastfeed to get cancer protection?
Research shows that each month of breastfeeding provides additional protection. The World Health Organization recommends at least 6 months of exclusive breastfeeding. Even shorter durations provide some benefit compared to no breastfeeding.
Will this research lead to new cancer treatments?
Possibly. By identifying specific molecules and pathways involved in cancer protection, scientists can develop new drugs or interventions targeting these pathways. However, this typically takes 10 to 15 years from discovery to clinical application.
Want to Apply This Research?
- Track breastfeeding duration in months for each child, noting start and end dates. This creates a personal record of a modifiable health factor linked to cancer risk reduction.
- For women planning pregnancy, use the app to set a breastfeeding goal duration based on health recommendations (WHO suggests 6 months minimum exclusive breastfeeding). Track progress and connect with lactation support resources within the app.
- Create a long-term health profile noting total lifetime breastfeeding months. Combine this with other cancer risk factors (family history, age at first birth, hormone use) to generate a personalized cancer risk assessment that updates as life circumstances change.
This research provides biological insight into why breastfeeding may reduce ovarian cancer risk but does not change current medical recommendations. Individual cancer risk depends on many factors including genetics, age, reproductive history, and lifestyle. Women concerned about ovarian cancer risk should discuss their personal risk factors and screening options with their healthcare provider. This study was observational and cannot prove that these molecules directly cause cancer protection. Results may not apply equally to all populations. Always consult with qualified healthcare professionals before making health decisions based on research findings.
This research translation is published by Gram Research, the science division of Gram, an AI-powered nutrition tracking app.